Paper36909895
Concentrations of selected acute phase proteins in patients with chronic venous insufficiency treated with Sulodexide. Part 1.
Kaczmarek B and 5 others. Postepy Dermatol Alergol, 2023. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Concentrations of selected acute phase proteins in patients with chronic venous insufficiency treated with Sulodexide. Part 1. Papers, record 36909895. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36909895
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Concentrations of selected acute phase proteins in patients with chronic venous insufficiency treated with Sulodexide. Part 1.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33807848 | Inflammatory Biomarkers in the Short-Term Prognosis of Venous Thromboembolism: A Narrative Review. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33807848 | PubMed |
| 2 | 11296331 | In situ hemodynamics of perforating veins in chronic venous insufficiency. | J Vasc Surg | 2001 | https://conductscience.org/library/papers/11296331 | PubMed |
| 3 | 25246013 | The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. | Circulation | 2014 | https://conductscience.org/library/papers/25246013 | PubMed |
| 4 | 7494366 | Risk factors for chronic venous insufficiency: a dual case-control study. | J Vasc Surg | 1995 | https://conductscience.org/library/papers/7494366 | PubMed |
| 5 | 11511615 | Lifestyle risk factors for lower limb venous reflux in the general population: Edinburgh Vein Study. | Int J Epidemiol | 2001 | https://conductscience.org/library/papers/11511615 | PubMed |
| 6 | 31989486 | Sulodexide for the Symptoms and Signs of Chronic Venous Disease: A Systematic Review and Meta-analysis. | Adv Ther | 2020 | https://conductscience.org/library/papers/31989486 | PubMed |
| 7 | 18572373 | Increasing awareness about venous disease: The American Venous Forum expands the National Venous Screening Program. | J Vasc Surg | 2008 | https://conductscience.org/library/papers/18572373 | PubMed |
| 8 | 10536489 | The effect of glycosaminoglycan sulodexide on oxidative stress and fibrinolysis in diabetes mellitus. | Sb Lek | 1998 | https://conductscience.org/library/papers/10536489 | PubMed |
| 9 | 14718318 | Relationship between deep venous thrombosis and the postthrombotic syndrome. | Arch Intern Med | 2004 | https://conductscience.org/library/papers/14718318 | PubMed |
| 10 | 15472590 | C-reactive protein and red cell aggregation correlate with late venous function after acute deep venous thrombosis. | J Vasc Surg | 2004 | https://conductscience.org/library/papers/15472590 | PubMed |
| 11 | 31114584 | Evolution of C-Reactive Protein. | Front Immunol | 2019 | https://conductscience.org/library/papers/31114584 | PubMed |
| 12 | 24936530 | Sulodexide: it is time for a program against chronic venous disease. | Int Angiol | 2014 | https://conductscience.org/library/papers/24936530 | PubMed |
| 13 | 34019218 | A brief, highly selective history of acute phase proteins as indicators of infection, inflammation and injury. | Inflammopharmacology | 2021 | https://conductscience.org/library/papers/34019218 | PubMed |
| 14 | 28688874 | The Role of Endothelial Dysfunction and Inflammation in Chronic Venous Disease. | Ann Vasc Surg | 2018 | https://conductscience.org/library/papers/28688874 | PubMed |
| 15 | 12936900 | Chronic venous disease in an ethnically diverse population: the San Diego Population Study. | Am J Epidemiol | 2003 | https://conductscience.org/library/papers/12936900 | PubMed |
| 16 | 24936532 | Glycosaminoglycan sulodexide modulates inflammatory pathways in chronic venous disease. | Int Angiol | 2014 | https://conductscience.org/library/papers/24936532 | PubMed |
| 17 | 24279420 | Sulodexide down-regulates the release of cytokines, chemokines, and leukocyte colony stimulating factors from human macrophages: role of glycosaminoglycans in inflammatory pathways of chronic venous disease. | Curr Vasc Pharmacol | 2014 | https://conductscience.org/library/papers/24279420 | PubMed |
| 18 | 10479629 | New insights into perforator vein incompetence. | Eur J Vasc Endovasc Surg | 1999 | https://conductscience.org/library/papers/10479629 | PubMed |
| 19 | 15723761 | The epidemiology of chronic venous insufficiency and varicose veins. | Ann Epidemiol | 2005 | https://conductscience.org/library/papers/15723761 | PubMed |
| 20 | 1430543 | Predisposing factors of varicose and telangiectatic leg veins. | J Dermatol Surg Oncol | 1992 | https://conductscience.org/library/papers/1430543 | PubMed |
Genes18
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36909895
GET https://conductscience.org/api/papers/v1/36909895/references?page=2